Innovent Biologics (HKSE:01801) Total Inventories : HK$1,059 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Total Inventories?

Innovent Biologics's total inventories for the quarter that ended in Dec. 2023 was HK$1,059 Mil. Innovent Biologics's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was HK$1,240 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Innovent Biologics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was HK$2.20.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Innovent Biologics's Days Inventory for the six months ended in Dec. 2023 was 327.66.

Inventory Turnover measures how fast the company turns over its inventory within a year. Innovent Biologics's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.56.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Innovent Biologics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.32.

Innovent Biologics Total Inventories Historical Data

The historical data trend for Innovent Biologics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Total Inventories Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

399.03

836.51

1,649.65

1,595.65

1,058.87

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Inventories	Get a 7-Day Free Trial										1,649.65	1,731.24	1,595.65	1,421.94	1,058.87

Innovent Biologics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Innovent Biologics (HKSE:01801) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Innovent Biologics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(11068.803	+	0.75 * 1100.222	+	0.5 * 1058.874	-	8859.367
-	0	-	0)	/	1621.83
=	2.20

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Innovent Biologics's Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	1240.409	/	690.887	*	365 / 2
	=	327.66

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Innovent Biologics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	690.887	/	1240.409
	=	0.56

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Innovent Biologics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	1240.409	/	3833.19
	=	0.32

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Innovent Biologics Total Inventories Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics (HKSE:01801) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

IVBXF:USA IVBIY:USA 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Executives

Jpmorgan Chase & Co.	2502 Approved lending agent
Yu De-chao Michael	2101 Beneficial owner
Temasek Holdings (private) Limited
Brown Brothers Harriman & Co.	2502 Approved lending agent
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Morgan Stanley	2201 Interest of corporation controlled by you
Citigroup Inc.	2201 Interest of corporation controlled by you
Shi Yi	2201 Interest of corporation controlled by you
Lav Asset Management (hong Kong) Limited	2102 Investment manager
Eight Roads Investments	2101 Beneficial owner
Fullerton Management Pte Ltd	2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited	2201 Interest of corporation controlled by you
Tls Beta Pte. Ltd.	2101 Beneficial owner

Innovent Biologics (HKSE:01801) Headlines

No Headlines